NEW YORK (Reuters Health) - Under-the-tongue or "sublingual" immunotherapy -- what doctors call SLIT -- is cost-effective for treating adults with pollen-induced respiratory allergy, according to a report.
SLIT is not officially in use in the United States, although some allergists use it "with satisfactory results," Dr. Giovanni Passalacqua from University of Genoa, Italy told Reuters Health. "The problem is formal, due to the fact that SLIT has not the approval of the FDA. Clinical studies endorsed by the FDA are currently ongoing to get the approval."
"In Europe the situation is completely different, and SLIT is widely used in many countries (e.g., Italy, Germany, France, Spain, Portugal, Greece, and Hungary)," Passalacqua said.